AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Peripheral Blood Stem Cell TransplantationTransplantation, AutologousHematopoietic Stem Cell TransplantationMultiple MyelomaHematopoietic Stem Cell MobilizationMelphalanTransplantation ConditioningTransplantation, HomologousCombined Modality TherapyGranulocyte Colony-Stimulating FactorLeukapheresisAntigens, CD34Hematologic NeoplasmsStem Cell TransplantationBlood Component RemovalAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideTreatment OutcomeMyeloablative AgonistsBusulfanGraft vs Host DiseaseLymphoma, Non-HodgkinBone Marrow TransplantationRemission InductionGraft SurvivalAntineoplastic Agents, AlkylatingHematopoietic Stem CellsEtoposideRecurrenceThiotepaSalvage TherapyVincristineCarmustineCytophagocytosisDisease-Free SurvivalIfosfamideNeoplasmsAmyloidosisBoronic AcidsSurvival RatePyrazinesRetrospective StudiesThalidomideStem CellsCytarabineHodgkin DiseaseDexamethasoneHematopoiesisSurvival AnalysisCord Blood Stem Cell TransplantationPrednisoneDoxorubicinTransplantation ChimeraTime FactorsTissue DonorsWhole-Body IrradiationAntineoplastic AgentsLymphoma, T-CellCancer VaccinesInfectionPlatelet CountPOEMS SyndromeHistocompatibilityBone MarrowCytotoxicity, ImmunologicFollow-Up StudiesImmunotherapyCarboplatinHistocompatibility TestingBone Marrow PurgingImmunosuppressive AgentsRecombinant ProteinsTransplantation, IsogeneicLeukemia, Myeloid, AcuteLymphocytes, Tumor-InfiltratingT-LymphocytesPlasma CellsImmunophenotypingFlow CytometryVidarabineLymphomaLeukemiaBlood Cell CountPrognosisAntigens, NeoplasmT-Lymphocytes, CytotoxicTumor Cells, CulturedProspective StudiesBlood Transfusion, AutologousFatal OutcomeCell Line, TumorBlood CellsCytomegalovirus InfectionsFeasibility StudiesGraft vs Leukemia EffectMyeloma ProteinsAntigens, CDImmunotherapy, ActiveMelanomaInterleukin-2
Solid tumorsLymphomaDestroyed tissue anGranulocyte-macropChemotherapyGraft-versus-HematologicHSCTLeukemiaMarrow TransplantationRefractory multiple myelomaTransplantsRelapseHematopoietic cell transplantationMelphalanMalignancyApheresisMalignant plasma cellsHigh-doseTherapiesPlasma cells of multiple myelomaMobilizationDonorsMalignanciesDonorEngraftmentImmunotherapyOutcomesAntigenClinicalHematologicalPatient's own cellsUmbilicalCord-bloodAcuteLymphomasHodgkin'sImmuneTherapyPediatricMobilize hematopoietic stemRenal failureBone Marrow TraNeutrophil recoveryEfficacyVitro2023OncologyCancersSurvivalAllogeneic hematopoietic sTreatmentsMaturationAntigensDiseases
Solid tumors4
  • Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. (nature.com)
  • Hematopoietic stem cell transplantation is also sometimes used for solid tumors (eg, some germ cell tumors) that respond to chemotherapy. (msdmanuals.com)
  • Solid tumors, autoimmune diseases, graft versus host disease (GvHD), genetic diseases and neurodegenerative diseases are investigated using many types of autologous and allogeneic cells with rapidly evolving cell engineering and editing approaches. (bdbiosciences.com)
  • The procedure has been used successfully to treat a variety of cancer types, including leukemia , lymphoma , multiple myeloma , myelodysplasia and solid tumors, such as testicular cancer or breast cancer . (ucsfhealth.org)
Lymphoma23
  • Other conditions treated with stem cell transplants include sickle cell disease, myelodysplastic syndrome, neuroblastoma, lymphoma, Ewing's sarcoma, desmoplastic small round cell tumor, chronic granulomatous disease, Hodgkin's disease and Wiskott-Aldrich syndrome. (wikipedia.org)
  • These advantages have established autologous HSCT as one of the standard second-line treatments for such diseases as lymphoma. (wikipedia.org)
  • Primary diagnoses were multiple myeloma (n = 14), Hodgkin's lymphoma (n = 7), non-Hodgkin's lymphoma (n = 2), acute myloid leukemia (n = 2), chronic lymphocytic leukemia (n = 1) and germ cell testis tumor (n = 1). (ogu.edu.tr)
  • [ 1 ] More than half of autologous transplantations are performed for multiple myeloma and non-Hodgkin lymphoma , and the vast majority of allogeneic transplants are performed for hematologic and lymphoid cancers. (medscape.com)
  • Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. (frontiersin.org)
  • Diffuse large B cell lymphoma (DLBCL) represents the most frequent form of non-Hodgkin's lymphoma (NHL). (frontiersin.org)
  • A stem cell transplant is often the best option to treat blood cancers, such as leukemia , lymphoma and multiple myeloma , as well as bone marrow failure syndromes like myelodysplastic syndrome . (mdanderson.org)
  • Autologous T cells genetically modified to express CARs targeting the B-cell antigen B-lymphocyte antigen CD19 (CD19) have caused complete remissions in a small number of patients with leukemia or lymphoma. (survivornet.com)
  • CAR-T cells, which incorporate an antibody-derived extracellular receptor and T cell derived intracellular signaling domains, have shown convincing outcomes in certain types of leukemia and lymphoma, including commercial licensure of CD19 CAR-Ts for the treatment of relapsed/ refractory large B cell lymphoma and acute lymphoblastic leukemia. (bdbiosciences.com)
  • The technique has also shown preliminarily promising outcomes in B cell acute lymphoblastic leukemia (B-ALL), B cell non-Hodgkin's lymphoma (B-NHL), chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma and multiple myeloma in clinical trials targeting CD19, CD20, CD22, CD30 and B-cell maturation antigen (BCMA), with many more under investigation. (bdbiosciences.com)
  • Bone marrow cancers such as multiple myeloma , leukaemia, and lymphoma , reduce the formation of HSCs in the bone marrow. (parkwaycancercentre.com)
  • T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. (uchicago.edu)
  • Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (uchicago.edu)
  • CONCLUSION: These data demonstrate the feasibility of allogeneic orautologous HSCT in heavily pretreated lymphoma patients who also receivedtositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Investigators will assess LP-284 as a treatment for those with B-cell non-Hodgkin lymphoma in a phase 1 trial. (cancernetwork.com)
  • Plerixafor Injection is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor in patients with non-Hodgkin's lymphoma or multiple myeloma and is the newest addition to the company's generic injectable oncology medicine portfolio, the largest in U.S. health care. (fresenius-kabi.com)
  • Plerixafor injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM). (fresenius-kabi.com)
  • The successful application of HSCT for diseases such as leukemia, lymphoma, myeloma, and inherited blood disorders underscored its broad applicability in clinical practice (Snowden et al. (revistadehematologia.org.mx)
  • The abstracts, including five oral presentations, highlight updated and interim efficacy and safety clinical trial results for ADCETRIS in both early- and advanced stage settings of classical Hodgkin lymphoma (cHL), and in patients with other CD30-expressing lymphomas and other rare cancers. (businesswire.com)
  • Additional data from real-world settings further support the efficacy, safety and impact of ADCETRIS treatment in its approved indications for multiple types of lymphoma. (businesswire.com)
  • Martí-Carvajal AJ, Cardona AF, Lawrence A. Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma. (medscape.com)
  • Serum Levels of the Chemokine CXCL13, Genetic Variation in CXCL13 and Its Receptor CXCR5, and HIV-Associated Non-Hodgkin B-Cell Lymphoma Risk. (medscape.com)
  • Computed tomography-based tumor volume in non-Hodgkin lymphoma: clinical correlation and comparison with magnetic resonance imaging. (medscape.com)
Destroyed tissue an1
  • The patient's own stored stem cells are then transfused into his/her bloodstream, where they replace destroyed tissue and resume the patient's normal blood-cell production. (wikipedia.org)
Granulocyte-macrop3
Chemotherapy23
  • In these cases, the recipient's immune system is usually destroyed with radiation or chemotherapy before the transplantation. (wikipedia.org)
  • Non-myeloablative, so-called mini transplant (microtransplantation) procedures, have been developed requiring smaller doses of preparative chemotherapy and radiation therapy, allowing HSCT to be conducted in the elderly and other patients who would otherwise be considered too weak to withstand a conventional treatment regimen. (wikipedia.org)
  • The patient is then treated with high-dose chemotherapy with or without radiotherapy with the intention of eradicating the patient's malignant cell population at the cost of partial or complete bone marrow ablation (destruction of patient's bone marrow's ability to grow new blood cells). (wikipedia.org)
  • The purpose is to deliver chemotherapy, immunotherapy, and/or radiation to eliminate malignancy, prevent rejection of new stem cells, and create space for the new cells. (medscape.com)
  • We extract blood cells, treat the cancer with high-dose chemotherapy , then place the cells back into the patient. (mdanderson.org)
  • Once the cancer is less active and the patient has been pre-treated with chemotherapy (known as conditioning), he or she receives the donor's healthy stem cells. (mdanderson.org)
  • Chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. (cancertreatmenttoday.org)
  • The choice of chemotherapy depends on several factors, including the patient's performance status, age, renal function, desire for inpatient or outpatient therapy, and likelihood of receiving future autologous stem cell transplantation. (medscape.com)
  • Results showed that adding quizartinib to standard chemotherapy with or without allogeneic hematopoietic stem cell transplantation, followed by continuation monotherapy for up to 3 years, resulted in improved overall survival. (medscape.com)
  • Stem cell therapy, or stem cell transplant, is a procedure that aims to restore blood-forming stem cells in patients who have undergone chemotherapy or radiotherapy . (parkwaycancercentre.com)
  • Autologous stem cell (patient's own stem cells) transplant is used to help patients recover from the effects of chemotherapy. (parkwaycancercentre.com)
  • Allogeneic stem cell (stem cells from a donor) transplant is used to help patients recover from the effects of chemotherapy and/or radiotherapy as well as to eradicate the remaining cancer cells in the patient after chemotherapy and/or radiotherapy. (parkwaycancercentre.com)
  • Chemotherapy or radiotherapy used to treat these cancers will destroy the HSCs in the bone marrow and abolish the body's ability to regenerate blood cells. (parkwaycancercentre.com)
  • The patient first receives a high dose of chemotherapy and/ or radiotherapy to eliminate the remaining cancer cells in the body. (parkwaycancercentre.com)
  • In allogeneic stem cell (stem cells from a donor) transplant, there is another benefit in addition to replenishing the HSCs in the bone marrow after chemotherapy or radiotherapy. (parkwaycancercentre.com)
  • The administration of bone marrow usually occurs after a patient has received high-dose chemotherapy or radiation. (ucsfhealth.org)
  • The new bone marrow cells are infused after the toxic effects of the chemotherapy or radiation have cleared, and these cells will re-create a healthy bone marrow. (ucsfhealth.org)
  • For autologous transplantation, the patient receives his or her own bone marrow or stem cells that were collected and frozen before admission for high-dose chemotherapy or radiation. (ucsfhealth.org)
  • Patients received a median of 3(range: 2-6) prior chemotherapy regimens (exclusive of tositumomab/iodine-131tositumomab) before or after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. (shengsci.com)
  • In April 1960, Dr. Álvaro Gómez-Leal, presented during the first meeting of the Agrupación Mexicana para el Estudio de la Hematología, A.C., data on a transplant of allogeneic stem cells in a patient with acute leukemia done in Monterrey, Mexico: the patient received high-dose chemotherapy followed by stem cells from the bone marrow of his brother, improving and obtaining remission for months but relapsing and subsequently died. (revistadehematologia.org.mx)
  • Patients with early-stage CLL are not treated with chemotherapy until they become symptomatic or display evidence of rapid progression of disease. (medscape.com)
  • Chemotherapy is not needed in CLL until patients become symptomatic or display evidence of rapid progression of disease. (medscape.com)
Graft-versus-3
  • Also, the incidence of patients experiencing rejection is very rare (and graft-versus-host disease impossible) due to the donor and recipient being the same individual. (wikipedia.org)
  • Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. (uchicago.edu)
  • Their ongoing Phase 2 study is evaluating whether infusion of mesenchymal stem cells (MSCs) can treat steroid-resistant acute graft-versus-host disease (GVHD) or poor graft function after HSCT. (drugdiscoverynews.com)
Hematologic6
  • The protective effect of seasonal influenza vaccination is reduced in patients with hematologic malignancy and recipients of an allogeneic hematopoietic stem cell transplant (HSCT) ( 5 , 6 ). (cdc.gov)
  • In the state of Victoria, after the initial 3 months of community transmission of pandemic (H1N1) 2009 virus, 50% of patients who died had an underlying hematologic malignancy ( 15 ). (cdc.gov)
  • elicits antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. (medscape.com)
  • Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. (uchicago.edu)
  • The cells are also being evaluated in a variety of other hematologic indications. (drugdiscoverynews.com)
  • Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable despite the advent of numerous new drugs such as proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies. (biomedcentral.com)
HSCT23
  • Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood in order to replicate inside of a patient and to produce additional normal blood cells. (wikipedia.org)
  • Autologous HSCT requires the extraction (apheresis) of hematopoietic stem cells (HSCs) from the patient and storage of the harvested cells in a freezer. (wikipedia.org)
  • Hematopoietic stem cell transplantation (HSCT) involves the intravenous infusion of hematopoietic stem cells in order to reestablish blood cell production in patients whose bone marrow or immune system is damaged or defective. (medscape.com)
  • Cells for HSCT may be obtained from the patient himself or herself (autologous transplant) or from another person, such as a sibling or unrelated donor (allogeneic transplant) or an identical twin (syngeneic transplant). (medscape.com)
  • The National Marrow Donor Program (NMDP), founded in 1986, and the World Marrow Donor Association (WMDA), founded in 1988, were established to (1) locate and secure appropriate unrelated-donor HSCT sources for patients by promoting volunteer donation of bone marrow and peripheral blood stem cells in the community and (2) promote ethical practices of sharing stem cell sources by need, rather than by geographic location of the donor. (medscape.com)
  • This, along with the development of unrelated cord blood transplantation and familial haploidentical transplantation methods, have improved the likelihood of finding an appropriate HSCT source in a timely manner. (medscape.com)
  • One needs to differentiate between tandem transplants, a planned sequence of two high dose treatments with HSCT salvage, and a second transplant, an approach of consolidating the first autologous HSCT with another HSCT ONLY if the first one appears partially effective. (cancertreatmenttoday.org)
  • We describe laboratory-confirmed influenza A pandemic (H1N1) 2009 in 17 hospitalized recipients of a hematopoietic stem cell transplant (HSCT) (8 allogeneic) and in 15 patients with malignancy treated at 6 Australian tertiary centers during winter 2009. (cdc.gov)
  • Ten (31.3%) patients were admitted to intensive care, and 9 of them were HSCT recipients. (cdc.gov)
  • There is a paucity of data examining the tolerance and outcome of hematopoietic stem cell transplantation (HSCT) for relapse after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • There is a paucity of data examining the tolerance andoutcome of hematopoietic stem cell transplantation (HSCT) for relapse aftertositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • Hematopoietic stem cell transplantation (HSCT) is a broad term that covers the transplantation of blood progenitor/stem cells from any source. (drugdiscoverynews.com)
  • Among the conditions HSCT can treat are: acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, myelodysplastic syndromes, multiple myeloma, non-Hodgkin lymphoma, Hodgkin disease, aplastic anemia and pure red-cell aplasia-but this list is not exhaustive. (drugdiscoverynews.com)
  • Other groups are also working on cell therapies for the treatment of poor graft function after HSCT. (drugdiscoverynews.com)
  • GVHD, which is common among allogenic HSCT and rare in autologous HSCT, can be acute or chronic. (drugdiscoverynews.com)
  • This was the first report of a hematopoietic stem cell transplantation (HSCT) conducted in Mexico, only 4 years after the pioneer work by E. Donnall Thomas in Cooperstown, New York, USA (Ruiz-Argüelles et al. (revistadehematologia.org.mx)
  • HSCT offers a way to reset the immune system, providing a novel approach to treating conditions such as multiple sclerosis, systemic sclerosis, and rheumatoid arthritis (Swart et al. (revistadehematologia.org.mx)
  • Hematopoietic stem cell transplantation (HSCT) affects serious risks for the patient, including death. (bvsalud.org)
  • Data were collected between March and September of 2016, through the evaluation of the medical records of 43 patients who underwent HSCT and developed some type of psychological distress. (bvsalud.org)
  • HSCT) has significantly modified the prognosis of when the pathological process involves BM or when patients with hereditary or acquired hematological, hematopoietic toxicity is the limiting factor in the oncological and immunological diseases and it is the aggressive treatment of the disease. (bvsalud.org)
  • HSCT make it an aggressive process, causing consists of painless intravenous infusion of healthy toxicity and can generate significant complications hematopoietic stem cells (HSC) extracted from bone and several side effects adding feelings of worry, marrow (BM), peripheral blood (PB) and placental anguish, anxiety, among others (KUBA et al. (bvsalud.org)
  • Also, drastic changes in daily living habits, qualified and responsible for the implementation of changes in body image, long duration of treatment, HSCT since 2004, agreed to the Brazilian Unified periods of hospitalization and protective isolation, Health System, which meets the needs of the feeling of loss of control, fear of death and lack of patients with an indication for transplantation. (bvsalud.org)
Leukemia20
  • It is most often performed for patients with certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia. (wikipedia.org)
  • It is well known that persistent immunodeficiency is a common feature in patients with leukemia. (biomedcentral.com)
  • Moreover, it has been shown that the PD-1 ligand (PD-L1) is highly expressed in leukemia cells. (biomedcentral.com)
  • In addition, PD-1/PD-L1 interactions contribute to functional T-cell impairment, which fails to elicit minimal residual disease and may be related to leukemia relapse. (biomedcentral.com)
  • Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. (uchicago.edu)
  • Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. (uchicago.edu)
  • Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. (uchicago.edu)
  • The safety profile of venetoclax following allogeneic hematopoietic stem cell transplantation in patients with chronic lymphocytic leukemia appears to be comparable with other reports in clinical trials. (cancernetwork.com)
  • Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. (shengsci.com)
  • Previous studies have shown that children with acute myeloid leukemia (AML) who developed mixed chimerism (MC) were at high risk for relapse after allogeneic stem-cell transplantation (allo-SCT). (shengsci.com)
  • Several patients with clinical features of chronic myeloid leukemia (CML) have fusion of the TEL (ETV6) gene on 12p13 with ABL on 9q34 and express a chimeric Tel-Abl protein that contains the same portion of the Abl tyrosine kinase fused to Tel, an Ets family transcription factor, rather than Bcr. (shengsci.com)
  • [ 1 ] First described in 1848, MM is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
  • We determined the capacity of the leukemia cell line K562 modified to express a membrane-bound form of interleukin (IL)-15 and 41BB ligand (K562-mb15-41BBL) to generate human NK cells with enhanced cytotoxicity. (aacrjournals.org)
  • Similar expansions could also be obtained from the peripheral blood of patients with acute leukemia undergoing therapy ( n = 11). (aacrjournals.org)
  • The expanded NK cells were significantly more potent than unstimulated or IL-2-stimulated NK cells against acute myeloid leukemia cells in vitro . (aacrjournals.org)
  • Therefore, Plerixafor is not intended for HSC mobilization and harvest in patients with leukemia. (fresenius-kabi.com)
  • Leukemia is a group of clonal diseases derived from a single cell with a genetic alteration in bone marrow or peripheral lymphoid tissue, and each type is determined by the specificity of the source cell. (sld.cu)
  • The objective of this research was to synthesize studies that characterize the clinical and epidemiological profile of patients with leukemia, the types of treatments used, duration and outcomes for the cases. (sld.cu)
  • It is concluded a prevalence of leukemia in pediatric patients, with a predominance of the subtype Acute Lymphoblastic Leukemia (ALL). (sld.cu)
  • Peripheral smear from a patient with chronic lymphocytic leukemia, small lymphocytic variety. (medscape.com)
Marrow Transplantation6
  • In 2006, 50,417 first HSCTs were recorded worldwide, according to a global survey of 1,327 centers in 71 countries conducted by the Worldwide Network for Blood and Marrow Transplantation. (wikipedia.org)
  • The Worldwide Network for Blood and Marrow Transplantation reported the millionth transplant to have been undertaken in December 2012. (wikipedia.org)
  • Bone Marrow Transplantation (2000) 26, 877-880. (nature.com)
  • Worldwide, approximately 90,000 first HSCTs-53% autologous and 47% allogeneic-are performed every year, according to the World Wide Network of Blood and Marrow Transplantation. (medscape.com)
  • Advances in the treatment of cancer and improvements in supportive care over the past 10 years have improved the results and tolerability of bone marrow transplantation. (ucsfhealth.org)
  • Between February 1986 and March 1990, 56 patients with relapsed Hodgkin's disease treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) received an autologous peripheral stem cell transplantation (PSCT) rather than an autologous bone marrow transplantation (ABMT) because each patient had a marrow abnormality, either hypocellularity or tumor involvement. (shengsci.com)
Refractory multiple myeloma4
  • It is indicated as monotherapy, in combination with dexamethasone, or in combination with lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma in patients who have received at least 1 prior line of therapy. (medscape.com)
  • Elranatamab is indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (medscape.com)
  • Updated results will also be presented from a phase 1 study of the investigational agent SEA-BCMA in patients with relapsed/refractory multiple myeloma. (businesswire.com)
  • Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma. (dukecancerinstitute.org)
Transplants12
  • Autologous transplants have the advantage of lower risk of infection during the immune-compromised portion of the treatment, since the recovery of immune function is rapid. (wikipedia.org)
  • To understand the different types of stem cell transplants and how they work, we spoke with Borje S. Andersson, M.D., Ph.D. Here's what he had to say. (mdanderson.org)
  • What are the types of stem cell transplants? (mdanderson.org)
  • Stem cell transplants fall into two categories: autologous and allogeneic. (mdanderson.org)
  • A tandem autologous transplant, also known as a double autologous transplant, requires the patient to undergo two planned autologous stem cell transplants within 6 months. (cancertreatmenttoday.org)
  • Preliminary results of several randomized trials comparing tandem and single autologous transplants, which have not been followed as long, have also shown superior event-free survival with the tandem regimen in most studies. (cancertreatmenttoday.org)
  • It appears that in patients with poor prognostic features, outcome is not improved with tandem transplants, so additional strategies need to be evaluated in this patient population. (cancertreatmenttoday.org)
  • Frequently, stem cells are taken from the pelvic bone, filtered, and stored under special conditions for future transplants. (parkwaycancercentre.com)
  • Additionally, stem cell transplants can also be categorised based on who donates the stem cells. (parkwaycancercentre.com)
  • BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. (uchicago.edu)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • At the time they performed the first transplants surprisingly little was known about hematopoietic stem cells, immune responses to transplants or the complex human leucocyte antigen system. (revistadehematologia.org.mx)
Relapse7
  • however, patients who experience early relapse, or who are refractory to initial immunochemotherapy have a poor prognosis ( 3 ). (frontiersin.org)
  • Background Patients with gene expression profiling-defined high-risk myeloma in relapse have poor outcomes with current therapies. (haematologica.org)
  • Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. (uchicago.edu)
  • e.g., thalidomide, lenalidomide, and pomalidomide), and monoclonal antibodies (e.g., daratumumab and elotuzumab) has provided numerous therapeutic avenues for patients with MM. Despite these advanced therapies, most MM patients eventually relapse and become resistant to treatment, and the length and depth of response to therapies typically decrease in the following relapse. (biomedcentral.com)
  • Here, we describe a myeloma patient who started a daily dietary supplement of curcumin when approaching her third relapse. (bmj.com)
  • Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. (nwbio.com)
Hematopoietic cell transplantation5
  • Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. (uchicago.edu)
  • Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Journal Article] Different impact of BCR-ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Ph+ALL with minimal residual disease. (nii.ac.jp)
Melphalan4
Malignancy10
  • Multiple myeloma (MM) is a malignancy of plasma cells. (survivornet.com)
  • T cells can be genetically modified to express chimeric antigen receptors (CARs) that specifically target malignancy-associated antigens. (survivornet.com)
  • These results demonstrate that CAR-expressing T cells have anti-malignancy activity in humans. (survivornet.com)
  • Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. (medscape.com)
  • Multiple myeloma (MM) is a lethal haematological malignancy with an incidence of 40-60 per 1,000,000 per year. (touchoncology.com)
  • Multiple myeloma (MM) is a hematological malignancy characterized by the proliferation of transformed monoclonal plasma cells in the bone marrow (BM) [ 1 ]. (biomedcentral.com)
  • Myeloma is a haematological malignancy which typically follows a relapsing-remitting course. (bmj.com)
  • Myeloma is a B-cell malignancy that is characterised by the monoclonal expansion and accumulation of abnormal plasma cells within the bone marrow. (bmj.com)
  • Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. (nwbio.com)
  • Risk of lymphoproliferative malignancy in relation to small intestinal histopathology among patients with celiac disease. (medscape.com)
Apheresis4
  • We evaluated hematopoietic stem cells according to CD34 expression and aldehyde dehydrogenase (ALDH) activity in peripheral blood and apheresis product samples from patients after mobilization with granulocyte-colony-stimulating factor (G-CSF) alone or G-CSF after high-dose cyclophosphamide (4 g/m(2) once daily, intravenously on day 1). (ogu.edu.tr)
  • Numbers of SSClo CD45(dim) CD34(hi) cells and SSClo ALDH(br) cells were highly correlated in both peripheral blood and apheresis products (P (ogu.edu.tr)
  • Plerixafor may cause mobilization of leukemic cells and subsequent contamination of the apheresis product. (fresenius-kabi.com)
  • Platelet counts should be monitored in patients who receive Plerixafor and then undergo apheresis. (fresenius-kabi.com)
Malignant plasma cells4
High-dose5
  • The damaged bone marrow will then be replenished with new stem cells to alleviate the side effects of the high-dose therapy. (parkwaycancercentre.com)
  • Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. (uchicago.edu)
  • Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. (uchicago.edu)
  • Dr. George Mathé explored the transplantation of bone marrow cells from healthy donors to treat patients accidentally irradiated at high dose, expanding the possibilities of this life-saving technique (Mathé et al. (revistadehematologia.org.mx)
  • Although there was evidence of a response to CTD (M-protein 34 g/L), bortezomib and dexamethasone treatment was initiated as an alternative, but this was discontinued after three cycles due to progressive disease (M-protein 49 g/L). The patient was then treated with lenalidomide and dexamethasone with the aim of reducing disease burden prior to high-dose therapy and autologous stem cell transplantation. (bmj.com)
Therapies8
  • Adults ages 18-73 who have been diagnosed with multiple myeloma that has not been controlled with standard therapies. (survivornet.com)
  • Engineered chimeric antigen receptor (CAR) T cell therapies (CAR-T) are now commercially available to treat certain leukemias and lymphomas. (bdbiosciences.com)
  • Investigational cell therapies are addressing a wide range of hematological malignancies. (bdbiosciences.com)
  • While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. (biomedcentral.com)
  • Natural killer (NK) cells can kill cancer cells in the absence of prior stimulation and hold considerable potential for cell-based therapies targeting human malignancies ( 1 - 4 ). (aacrjournals.org)
  • There is an unmet need to develop novel therapies for refractory/relapsed MM. In the past few years, chimeric antigen receptor (CAR)-modified T cell therapy for MM has shown promising efficacy in preclinical and clinical studies. (biomedcentral.com)
  • To help control symptoms and enhance quality of life, some patients use complementary therapies as an adjunct to their conventional therapy. (bmj.com)
  • Among PSCs, the donors available for induced pluripotent stem cells (iPSCs) are greatest, providing a potentially universal cell source for all types of cell therapies including cancer immunotherapies using natural killer (NK cells). (molcells.org)
Plasma cells of multiple myeloma1
Mobilization6
  • According to our data, numbers of SSClo ALDH(br) cells are in very good agreement with numbers of SSClo CD45(dim) CD34(hi) cells and can be a predictor of stem cell mobilization. (ogu.edu.tr)
  • The patients were evaluated based on PBSC mobilization and collection parameters, including overall collection results, CD34 + cell levels in peripheral blood, leukapheresis (LP) delays, overall number of LP sessions, and the rate of rescue mobilization with plerixafor. (biomedcentral.com)
  • However, during stem cell mobilization and -collection, no study-specific therapeutic intervention was performed. (biomedcentral.com)
  • PBSC mobilization should be performed after induction therapy to ensure collection of a sufficient number of cells. (biomedcentral.com)
  • In patients treated with Plerixafor in combination with G-CSF for HSC mobilization, tumor cells may be released from the marrow and subsequently collected in the leukapheresis product. (fresenius-kabi.com)
  • 1989). Hematopoietic stem cells could be harvested easier from peripheral blood after mobilization with G-CSF (Sheridan et al. (revistadehematologia.org.mx)
Donors4
Malignancies1
  • The role of PD-1 and PD-L1 in T-cell immune suppression and the potential for immunotherapy via blocking PD-1 and PD-L1 in hematological malignancies are also reviewed. (biomedcentral.com)
Donor19
  • It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from an identical twin). (wikipedia.org)
  • In 2014, according to the World Marrow Donor Association, stem-cell products provided for unrelated transplantation worldwide had increased to 20,604 (4,149 bone-marrow donations, 12,506 peripheral blood stem-cell donations, and 3,949 cord-blood units). (wikipedia.org)
  • Where do allogeneic stem cell transplant donor cells come from? (mdanderson.org)
  • With a peripheral blood cell transplant, the donor receives growth factor shots to stimulate the bone marrow to push the stem cells into the blood. (mdanderson.org)
  • This allows us to collect more cells in a short period, decrease patient/donor downtime and freeze the cells for future use. (mdanderson.org)
  • For many patients who don't have a well-matched, healthy donor, a cord blood transplant is a viable option. (mdanderson.org)
  • If the donor cells aren't a close enough match, the patient's body may recognize the donor cells as foreign and reject them. (mdanderson.org)
  • Or, the cells from the donor may recognize the new body as foreign and attack. (mdanderson.org)
  • MSC mediated bone formation involves in both donor and recipient cells, but only recipient cells contribute to marrow element formation. (ca.gov)
  • Hematopoietic stem cell transplantation may be autologous (using the patient's own cells) or allogeneic (using cells from a donor). (msdmanuals.com)
  • It gives the patient a whole new and healthy immune system of the donor. (parkwaycancercentre.com)
  • The donor immune cells can kill the leftover cancer cells and will exert a "graft-versus-cancer" effect, keeping the cancer cells in check. (parkwaycancercentre.com)
  • A donor, either related or unrelated to the patient, who donates the stem cells for transplant. (parkwaycancercentre.com)
  • Finding a donor with suitable stem cells is critical to avoid graft rejection or graft-versus-host syndrome. (parkwaycancercentre.com)
  • Many factors dictate whether the donor stem cells are suitable for the recipient but the most important one is the human leukocyte antigen (HLA) system. (parkwaycancercentre.com)
  • A bone marrow transplant is the replacement of diseased or damaged bone marrow cells with new bone marrow cells that have been stored, frozen or obtained from a bone marrow donor. (ucsfhealth.org)
  • For allogeneic transplantation, the patient receives bone marrow or stem cells from a donor who may or may not be a relative. (ucsfhealth.org)
  • Four patients were alive withno evidence of disease (three matched unrelated donor and one matched relateddonor). (cancernetwork.com)
  • of these, 53 percent are autologous (taken from the patient) and 47 percent are allogenic (taken from a donor other than the patient). (drugdiscoverynews.com)
Engraftment6
  • We conclude that in spite of rapid engraftment, non-hematological toxicities and infections remain important limitations for further reduction of the length of patient hospitalization in a significant number of patients after PBSCT. (nature.com)
  • We also investigated the relationship between the number of SSClo CD45(dim) CD34(hi) cells, SSClo ALDH(br) cells and engraftment. (ogu.edu.tr)
  • Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. (uchicago.edu)
  • All patients except two who received reduced intensity had severe mucositis.Reversible veno-occlusive disease of the liver also developed in two patients.There was one death from graft-vs-host disease and no regimen-related mortality.Engraftment was prompt, with a median recovery of absolute neutrophil count to ³ 500/µL of 12 days (range: 11-18 days). (cancernetwork.com)
  • Incomplete engraftment (poor graft function) requires the patient to undergo more transfusions of red cells or platelets. (drugdiscoverynews.com)
  • One trial is testing whether MSCs with or without peripheral blood stem cells could treat poor graft function and delayed platelet engraftment. (drugdiscoverynews.com)
Immunotherapy6
  • Building off experience in hematopoietic stem cell transplant and exploiting advances in genetic engineering, genome editing, immunology, immunotherapy, stem cell biology, understanding disease mechanisms and cell therapy manufacturing, considerable progress has been made with hundreds of clinical trials underway. (bdbiosciences.com)
  • Infusions of natural killer (NK) cells are an emerging tool for cancer immunotherapy. (aacrjournals.org)
  • Immunotherapy utilizing T cell immunity has become a new treatment to eliminate cancer cells. (biomedcentral.com)
  • Chimeric antigen receptor (CAR) T cell therapy has emerged as a novel immunotherapy which modifies T cells with CAR, an artificial fusion protein that incorporates an extracellular antigen recognition domain, a transmembrane domain, and an intracellular domain including costimulation and signaling components [ 4 , 5 ]. (biomedcentral.com)
  • Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience. (nwbio.com)
  • Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. (nwbio.com)
Outcomes3
  • We describe in detail the clinical features, treatment, and outcomes of immunocompromised patients hospitalized in 6 tertiary centers in Australia during winter 2009. (cdc.gov)
  • In an effort to improve long-term outcomes, some myeloma patients seek to use dietary supplements, mostly for palliative purposes. (bmj.com)
  • Banchereau J, Ueno H, Dhodapkar M, Connolly J, Finholt JP, Klechevsky E, Blanck JP, Johnston DA, Palucka AK, Fay J. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. (nwbio.com)
Antigen10
  • Antibody- and T-cell-based approaches to targeting of B-cell maturation antigen have shown efficacy. (merckmanuals.com)
  • Elranatamab is an antibody that binds to both CD3 on T-cells and B-cell maturation antigen (BCMA), which are expressed on the surface of multiple myeloma cells. (medscape.com)
  • It is a bispecific humanized monoclonal antibody against CD3, a T-cell surface antigen, and GPRC5D (human G-protein coupled receptor family C group 5 member D), a tumor-associated antigen with potential antineoplastic activity. (medscape.com)
  • Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. (shengsci.com)
  • The work of Jean Dausset, whose discovery of the human leukocyte antigen (HLA) system revolutionized our understanding of tissue compatibility for transplantation (Dausset J, 1958). (revistadehematologia.org.mx)
  • Several antigens have been used as targets for CAR-T cell therapy against MM, including B cell maturation antigen (BCMA), CD19, CD138, signaling lymphocytic activation molecule 7 (SLAM7), and immunoglobulin light chains. (biomedcentral.com)
  • Two main advantages of BCMA as an antigen for CAR-T therapy are the potential reduction of on-target/off-tumor toxicity and the lack of antigen-dependent reduction in CAR-T cell expansion [ 16 ]. (biomedcentral.com)
  • Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. (nwbio.com)
  • Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. (nwbio.com)
  • Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. (nwbio.com)
Clinical16
  • Each of those cell sources has specific advantages and disadvantages, and each has found particular clinical applications. (medscape.com)
  • Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness. (frontiersin.org)
  • Cell-based therapy using systemic infusion of GMSC in experimental colitis significantly ameliorated both clinical and histopathological severity of the colonic inflammation, restored the injured gastrointestinal mucosal tissues, reversed diarrhea and weight loss, and suppressed the overall disease activity in mice. (ca.gov)
  • We examined the clinical outcome of three autologous PDLP-treated patients in an effort to provide primary knowledge on the effectiveness of this treatment approach and preliminary clinical evidence for randomized controlled trial in the future. (ca.gov)
  • This study demonstrated clinical and experimental evidences supporting a potential efficacy and safety of utilizing autologous PDL cells in the treatment of human periodontitis. (ca.gov)
  • To support evidence-based clinical guidelines on erythropoietin use for anemia in oncology, we conducted systematic reviews of controlled trials on four patient groups. (cancernetwork.com)
  • T cell-targeted immunomodulators such as monoclonal antibodies against PD-1 or CTLA4 may be used in combination with CAR-T cells in clinical trials. (bdbiosciences.com)
  • Scientists working in basic, translational, and clinical cancer metabolism research are invited to join the Academy in New York on April 17th to discuss the intersection between cell signaling and metabolism. (nyas.org)
  • Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support. (shengsci.com)
  • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines also recommend the use of serum free light chain assay and plasma cell fluorescence in situ hybridization (FISH) on bone marrow: del 13, del 17p13, t(4;14), t(11;14), t(14;16), t(14;20), 1q21 amplification, 1p deletion as part of the initial diagnostic workup. (medscape.com)
  • Patients were treated within the randomized phase III clinical trials GMMG-HD6 (NCT02495922, 24/06/2015) and GMMG-HD7 (NCT03617731, 24/07/2018). (biomedcentral.com)
  • We therefore adapted the K562-mb15-41BBL stimulation method to large-scale clinical-grade conditions, generating large numbers of highly cytotoxic NK cells. (aacrjournals.org)
  • The results that we report here provide rationale and practical platform for clinical testing of expanded and activated NK cells for cell therapy of cancer. (aacrjournals.org)
  • Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. (nwbio.com)
  • We look forward to other payers recognizing the clinical benefits of lumbar TDR enabling patients to maintain spinal motion and avoid adjacent segment disease. (ukpropertyguides.com)
  • 14: Laurell H, Hansson LE, Gunnarsson U. Impact of clinical experience and diagnostic performance in patients with acute abdominal pain. (cancercentrum.se)
Hematological2
Patient's own cells1
  • An autologous stem cell transplant uses the patient's own cells for treatment. (mdanderson.org)
Umbilical6
Cord-blood3
  • Because cord blood contains immature stem cells, HLA matching appears less crucial than for the other types of hematopoietic stem cell transplantation. (msdmanuals.com)
  • One concern about the procedure is that immune cells in cord blood do not have experience with the viruses responsible for latent infections, leading to a higher percentage of naive T cells and thus increased vulnerability to reactivation of cytomegalovirus or Epstein-Barr virus infection. (msdmanuals.com)
  • The baby will not be harmed in any way during the cord blood collection. (parkwaycancercentre.com)
Acute1
  • The recommended starting dose of bivalirudin for medically managed patients with acute coronary syndrome (ACS) is an intravenous bolus of 0.1 mg/kg followed by an infusion of 0.25 mg/kg/h. (medthority.com)
Lymphomas1
  • Two courses of four weekly infusions of rituximab with or without interferon-2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. (cancercentrum.se)
Hodgkin's2
  • The actuarial event-free survival for these 56 patients at 3 years was 37% and was at least as good as that reported for relapsed Hodgkin's disease patients treated with CBV and ABMT. (shengsci.com)
  • CBV and PSCT for patients with relapsed Hodgkin's diseases who have marrow hypocellularity in traditional harvest sites or histopathologic evidence of BM metastases can result in long-term event-free survival. (shengsci.com)
Immune9
  • During the neutropenic phase (2-4 wk) the patient essentially has no effective immune system. (medscape.com)
  • The transplanted cells kill any remaining cancer cells and restore the patient's immune system. (mdanderson.org)
  • Such immune dysfunction may be due to a disorder in thymic output function (in particular in young patients), which results in a lower level of naive T-cells in the peripheral blood available for an immune response to the proliferation and abnormal expression of the T cell receptor (TCR) repertoire. (biomedcentral.com)
  • Moreover, increasing data have shown that peripheral T-cell tolerance is an essential property of the specific immune response to tumor cells. (biomedcentral.com)
  • GMSC can function as an immunomodulatory and anti-inflammatory component of the immune system in vivo and is a promising cell source for cell-based treatment in experimental inflammatory diseases. (ca.gov)
  • It uses a person s own T cells, which are part of the immune system. (survivornet.com)
  • 1957). This pioneering work laid the foundation for the exploration of hematopoietic stem cells and their role in treating diseases of the blood and immune system. (revistadehematologia.org.mx)
  • We use these genomes and transcriptomes to show that unlike other wild waterfowl, black swans lack an expanded immune gene repertoire, lack a key viral pattern-recognition receptor in endothelial cells and mount a poorly controlled inflammatory response to highly pathogenic avian influenza. (bvsalud.org)
  • Furthermore, T cells and NK cells complement each other in that certain immune suppression mechanisms taken by tumor cells that are effective against T cells, such as the downregulation of human leukocyte antigens (HLA), have proven to be stimulatory for NK cells. (molcells.org)
Therapy15
  • Despite this heterogeneous response, blood pre-infusion biomarkers predicting responsiveness to CART cell therapy are currently understudied. (frontiersin.org)
  • Bisphosphonate related osteonecrosis of the jaw (BRONJ) is a recently described adverse side effect of bisphosphonate therapy, with an estimated 94% of cases reported in the oncologic patients receiving intravenous nitrogen-containing bisphosphonates (BP). (ca.gov)
  • Two hundred thirty-one patients with symptomatic myeloma were enrolled in Total Therapy I between 1990 and 1995 (Barlogie et al. (cancertreatmenttoday.org)
  • Oseltamivir resistance in 4 (13.3%) of 30 patients who were administered oseltamivir highlights the need for ongoing surveillance of such resistance and further research on optimal antiviral therapy in the immunocompromised. (cdc.gov)
  • In patients with renal failure or highly aggressive disease, therapy with vincristine, Adriamycin (doxorubicin), and dexamethasone (VAD) may be preferred. (medscape.com)
  • Tremendous advances have been made in cell therapy in the past decade. (bdbiosciences.com)
  • A common theme in cell therapy is the need to characterize and understand cell phenotypes and heterogeneity at every step of the process. (bdbiosciences.com)
  • The ORR was 64% in patients with prior T-cell redirecting therapy. (medscape.com)
  • The American Society for Transplantation and Cellular Therapy (ASTCT) guidelines recommend a collection target of 3-5 × 10 6 CD34+ cells/kg. (medscape.com)
  • A small number of stem cells can be found in the blood, and these can be collected for stem cell therapy. (parkwaycancercentre.com)
  • Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. (uchicago.edu)
  • this means that the tumour can reform after the end of therapy, leading to disease recurrence. (touchoncology.com)
  • This study demonstrates that stem cell collection is feasible after prolonged induction with isatuximab-RVd without collection failures and might be further explored as induction therapy. (biomedcentral.com)
  • Collectively, although scientists are increasingly aware of mitochondria's dynamic and transferable capabilities of mitochondria, the unclear mechanism and effectiveness of mitochondrial transfer/transplantation therapy limit its widespread application in diseases. (biomedcentral.com)
  • Furthermore, the toxicities of CAR-T cell therapy are manageable. (biomedcentral.com)
Pediatric1
  • Candidates for HSCTs include pediatric cases where the patient has an inborn defect such as severe combined immunodeficiency or congenital neutropenia with defective stem cells, and also children or adults with aplastic anemia who have lost their stem cells after birth. (wikipedia.org)
Mobilize hematopoietic stem1
Renal failure1
  • Multiple myeloma (MM) is a malignant plasma cell disorder with debilitating symptoms related to anemia, immunosuppression, bone destruction, and renal failure. (haematologica.org)
Bone Marrow Tra1
Neutrophil recovery3
  • We could not find a relationship between the transplanted SSClo CD45(dim) CD34(hi) cell dose or SSClo ALDH(br) cell dose and platelet or neutrophil recovery. (ogu.edu.tr)
  • The optimal thresholds for SSClo CD45(dim) CD34(hi) cells were 5.40 x 106/kg for neutrophil recovery and 7.22 x 106/kg for platelet recovery. (ogu.edu.tr)
  • The optimal thresholds for SSClo ALDH(br) cells were 6.53 x 106/kg for neutrophil recovery and 8.72 x 106/kg platelet recovery. (ogu.edu.tr)
Efficacy1
  • In the SIMPLIFY-1 multicenter, randomized, double-blind, phase III study, safety and efficacy of momelotinib was compared with ruxolitinib in 432 patients with myelofibrosis who had not received prior treatment with a JAK inhibitor. (medscape.com)
Vitro3
  • In vitro , CD3 + CD8 + CD27 - CD28 - compared to CD3 + CD8 + CD27 + CD28 + CART cells displayed similar CD19 + target cell-specific cytotoxicity, but were hypoproliferative and produced less cytotoxic cytokines (IFN-γ and TNF-α). (frontiersin.org)
  • We have constructed a novel anti-BCMA CAR that can specifically recognize BCMA- expressing target cells in vitro and eradicate BCMA-expressing tumors in mice. (survivornet.com)
  • We tested whether natural killer cells expanded by co-culture with K562 cells transfected with 41BBL and membrane-bound interleukin-15 could kill myeloma cells with a high-risk gene expression profile in vitro and in a unique model which recapitulates human myeloma. (haematologica.org)
20231
  • Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase, Blood Advances, Vol.7, No.6, 1019-1032, 2023. (matci.jp)
Oncology1
  • The company plans to bring more oncology and oncology supportive care products to U.S. patients to further support patient care and choice. (fresenius-kabi.com)
Cancers2
  • Blood cancers multiply uncontrollably, hindering the growth of these cells. (mdanderson.org)
  • Stem cell transplant is often a part of the treatment plan for blood cancers. (parkwaycancercentre.com)
Survival6
  • The final analysis of the landmark French IFM-94 trial demonstrated that double transplantation led to improved survival compared with single transplantation in patients with previously untreated myeloma. (cancertreatmenttoday.org)
  • Reversible proteasome inhibition disrupts pathways supporting cell growth, thus decreasing cancer cell survival. (medscape.com)
  • 1 Significant advances have been made by combining novel agents with autologous peripheral blood stem cell transplantation which allows for long-term disease-free survival in the majority of transplant-eligible patients. (haematologica.org)
  • The 30 patients who had no marrow metastases at the time of PSC harvesting had an actuarial event-free survival of 47%, while those 26 patients with marrow metastases had a significantly different actuarial event-free survival of 27% (P = .02). (shengsci.com)
  • Intercellular mitochondrial transfer can be regarded as an extension of intracellular mitochondrial movement or intercellular communication, which undoubtedly increases the mtDNA content of the recipient cells and restores the respiration and survival of the recipient cells. (biomedcentral.com)
  • Despite this, myeloma remains incurable, with a median overall survival of 5.2 years from diagnosis. (bmj.com)
Allogeneic hematopoietic s1
  • Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. (uchicago.edu)
Treatments2
  • There are complications of serial transfusions of either of these cell types, and a patient needs intense prophylactic treatments to protect from infections if his or her white counts are low. (drugdiscoverynews.com)
  • SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments. (dukecancerinstitute.org)
Maturation3
  • Based on their functional outcome, co-signaling molecules can be divided as co-stimulators and co-inhibitors, which positively and negatively control the priming, growth, differentiation and functional maturation of a T-cell response. (biomedcentral.com)
  • Moreover, BCMA plays an essential role in regulating B cell maturation and differentiation into plasma cells. (biomedcentral.com)
  • Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. (nwbio.com)
Antigens3
  • We all have protein structures called human leukocyte antigens (HLA) on our cells' surfaces. (mdanderson.org)
  • 1 T cells are engineered to express CARs through viral vectors, enabling them to recognize specific target antigens. (bdbiosciences.com)
  • Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. (nwbio.com)
Diseases4
  • it is reserved for patients with life-threatening diseases. (wikipedia.org)
  • Human orofacial bone-derived mesenchymal stem cells (OMSCs) showed distinct differentiation traits from mesenchymal stem cells (MSCs) derived from long bones, mouse OMSCs have not been isolated due to technical difficulties, which in turn precludes using mouse models to study orofacial diseases. (ca.gov)
  • The discrepancy in bone development between orofacial bones and long axial/appendicular bones give rises to specific diseases in the orofacial bone region, such as periodontitis, cherubism, and hyperparathyroid jaw tumor syndrome, which only affect the jaw bones. (ca.gov)
  • In addition, we also discuss the existing methods of artificial mitochondrial transfer/transplantation (AMT/T) and their therapeutic effects on diseases to explore the potential applications of mitochondrial transfer and transplantation in the treatment of mitochondrial-related diseases, mitochondrial diseases, and cancer. (biomedcentral.com)